Overview

Price chart · mood · technical indicators

TVTX

Travere Therapeutics Incstock Healthcare

Biotechnology

$45.20207.07%Current Market Mood:Strong Bullish

Market Mood

Price Range (1Y)

$13.88$48.61

Current: $45.20

Idea: EMA

1Y Return

+54.7%

Sharpe 3Y

0.67

Market Comparison

vs Healthcare Sector & Biotechnology Industry

TVTX

+207.07%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—Forward 61.73

EPS (TTM)$-0.500.0% YoY

Profit margin-4.0%HEALTHCARE

Market cap$3.99BMid cap

Wall Street coverage

$54.14median target· current $7.83 (+591.4%)15 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 61.73
PEG ratio: —
P/B: 42.42
P/S (TTM): 7.45
EV/EBITDA: 110.32

Profitability & growth

ROE (TTM): -69.4%
Operating margin: -29.0%
Revenue growth YoY: 55.6%
Dividend yield: —
Beta: 1.14

Last earnings

May 4, 2026 · Estimate $-0.30 · Reported $-0.40

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Travere Therapeutics Inc

Company profile

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 3611 VALLEY CENTRE DRIVE, SAN DIEGO, CA
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$3.99B

Shares outstanding$93.0M

52W high$48.61

52W low$13.88

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

Overview

TVTX

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Travere inks licensing deal worth up to $1.1B with China’s Everest Medicines

TVTX Reiterated by Wedbush -- Price Target Maintained at $55

AASTOCKS Financial News - Travere Therapeutics, Inc. (TVTX)

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion

Travere inks licensing deal worth up to $1.1B with China’s Everest Medicines

Travere Therapeutics signs license deal with Everest Medicines for BTK inhibitor

Travere Therapeutics Enters Into Exclusive Licensing Agreement With Everest Medicines For Civorebrutinib A Potential Best-In-Class Btk Inhibitor For Rare Kidney Diseases

Travere Therapeutics (TVTX) inks global BTK inhibitor deal with Everest Medicines

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Why Travere Therapeutics (TVTX) Is Up 6.2% After New FILSPARI IgA Nephropathy Patent Protection

A Look At Travere Therapeutics (TVTX) Valuation After New FILSPARI Patent Protection Into 2037

A Look At Travere Therapeutics (TVTX) Valuation After New FILSPARI Patent Protection Into 2037

A Look At Travere Therapeutics (TVTX) Valuation After New FILSPARI Patent Protection Into 2037

Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $54.21, Implies 14% Upside

Travere receives patent allowance for Filspari IgA nephropathy use

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy

Travere Therapeutics (TVTX) director receives stock and option awards

[Form 4] Travere Therapeutics, Inc. Insider Trading Activity

[Form 4] Travere Therapeutics, Inc. Insider Trading Activity

About Travere Therapeutics Inc

Classification

Company profile

TVTX

Market Comparison

TVTX Market Analysis

Overview

TVTX

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Travere inks licensing deal worth up to $1.1B with China’s Everest Medicines

TVTX Reiterated by Wedbush -- Price Target Maintained at $55

AASTOCKS Financial News - Travere Therapeutics, Inc. (TVTX)

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion

Travere inks licensing deal worth up to $1.1B with China’s Everest Medicines

Travere Therapeutics signs license deal with Everest Medicines for BTK inhibitor

Travere Therapeutics Enters Into Exclusive Licensing Agreement With Everest Medicines For Civorebrutinib A Potential Best-In-Class Btk Inhibitor For Rare Kidney Diseases

Travere Therapeutics (TVTX) inks global BTK inhibitor deal with Everest Medicines

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Why Travere Therapeutics (TVTX) Is Up 6.2% After New FILSPARI IgA Nephropathy Patent Protection

A Look At Travere Therapeutics (TVTX) Valuation After New FILSPARI Patent Protection Into 2037

A Look At Travere Therapeutics (TVTX) Valuation After New FILSPARI Patent Protection Into 2037

A Look At Travere Therapeutics (TVTX) Valuation After New FILSPARI Patent Protection Into 2037

Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $54.21, Implies 14% Upside

Travere receives patent allowance for Filspari IgA nephropathy use

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy

Travere Therapeutics (TVTX) director receives stock and option awards

[Form 4] Travere Therapeutics, Inc. Insider Trading Activity

[Form 4] Travere Therapeutics, Inc. Insider Trading Activity

About Travere Therapeutics Inc

Classification

Company profile

TVTX

Market Comparison